Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01016860 · ClinicalTrials.gov registry record · Phase 1
OSI-906 and Irinotecan in Patients With Advanced Cancer
A Phase 1 study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01016860: Clinical Trial Phase 1 study, sponsored by University of Colorado, Denver.
NCT01016860 is a Phase 1 study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01016860, a Phase 1 study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study plans to learn more about an investigational drug called OSI-906. OSI-906 is being looked at to see if it could be a treatment for advanced cancer. "The FDA is the U.S. government agency that reviews the results of research of drugs and decides if it can be sold in the U.S. OSI-906 has been given to over 185 people with cancer.
Interventions
- DRUG irinotecan
- DRUG OSI-906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Why NCT01016860 stopped before completion
NCT01016860 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which irinotecan is the first listed.
NCT01016860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01016860 about?
NCT01016860 is a clinical study titled "OSI-906 and Irinotecan in Patients With Advanced Cancer". This study plans to learn more about an investigational drug called OSI-906. OSI-906 is being looked at to see if it could be a treatment for advanced cancer. "The FDA is the U.S. government agency that reviews the results of research of drugs and decides if it can be sold in the U.S. OSI-906 has be...
What is the current status of trial NCT01016860?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-12. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01016860?
The interventions under investigation include: irinotecan (DRUG), OSI-906 (DRUG).
Who is sponsoring clinical trial NCT01016860?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01016860's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia